TTI-101 is under clinical development by Tvardi Therapeutics and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase II drugs for Pancreatic Ductal Adenocarcinoma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the TTI-101 LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TTI-101 overview

TTI-101 is under development for the treatment of unspecified cancers, solid tumors including breast cancer, metastatic hormone receptor-positive and HER2-negative breast cancer, head and neck squamous cell carcinoma, non-small cell lung cancer, metastatic hepatocellular carcinoma, colorectal cancer, gastric adenocarcinoma and melanoma, cachexia, skin, liver, inflammation, idiopathic pulmonary fibrosis, scleroderma and oropharyngeal cancer. It is administered intravenously and orally (in the form of hard capsule). The drug candidate act by targeting signal transducer and activator of transcription (STAT) 1 and 3. It was also under development for the treatment of inflammatory bowel disease. 

Tvardi Therapeutics overview

Tvardi Therapeutics., is a biotechnology company that developing a new class of breakthrough medicines for diverse cancers. The company is headquartered in United States.

For a complete picture of TTI-101’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.